Bill Text: TX HB4288 | 2023-2024 | 88th Legislature | Introduced
Bill Title: Relating to a study on the use of alternative therapies for treating post-traumatic stress disorder.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Introduced - Dead) 2023-03-21 - Referred to Public Health [HB4288 Detail]
Download: Texas-2023-HB4288-Introduced.html
| 88R11662 LRM-F | ||
| By: Raymond | H.B. No. 4288 | |
|
|
||
|
|
||
| relating to a study on the use of alternative therapies for treating | ||
| post-traumatic stress disorder. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. Sections 1(b), (c), (d), and (f), Chapter 983 | ||
| (H.B. 1802), Acts of the 87th Legislature, Regular Session, 2021, | ||
| are amended to read as follows: | ||
| (b) The commission, in collaboration with Baylor College of | ||
| Medicine and in partnership with a military veterans hospital, [ |
||
| a medical center that provides medical care to veterans, or a | ||
| facility licensed in this state that provides Ketamine-related | ||
| mental health services, shall conduct a study on the efficacy of | ||
| using alternative therapies, including the use of | ||
| 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and | ||
| ketamine, in the treatment of veterans and other identified | ||
| individuals who suffer from post-traumatic stress disorder. | ||
| (c) In conducting the study described by Subsection (b) of | ||
| this section, the commission in collaboration with the Baylor | ||
| College of Medicine shall: | ||
| (1) perform a clinical trial on the therapeutic | ||
| efficacy of using psilocybin in the treatment of | ||
| treatment-resistant post-traumatic stress disorder in veterans and | ||
| other identified individuals; [ |
||
| (2) prescribe standardized protocols for each | ||
| researcher or research organization participating in the study; and | ||
| (3) review current literature regarding: | ||
| (A) the safety and efficacy of | ||
| 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and | ||
| ketamine in the treatment of post-traumatic stress disorder; and | ||
| (B) the access veterans and other identified | ||
| individuals have to 3,4-methylenedioxymethamphetamine (MDMA), | ||
| psilocybin, and ketamine for treatment of post-traumatic stress | ||
| disorder in the United States. | ||
| (d) The commission shall prepare and submit to the governor, | ||
| the lieutenant governor, the speaker of the house of | ||
| representatives, and each member of the legislature: | ||
| (1) quarterly reports on the progress of the study | ||
| conducted under this section; and | ||
| (2) not later than December 1, 2026 [ |
||
| report containing the results of the study conducted under this | ||
| section and any recommendations for legislative or other action. | ||
| (f) This Act expires September 1, 2027 [ |
||
| SECTION 2. This Act takes effect immediately if it receives | ||
| a vote of two-thirds of all the members elected to each house, as | ||
| provided by Section 39, Article III, Texas Constitution. If this | ||
| Act does not receive the vote necessary for immediate effect, this | ||
| Act takes effect September 1, 2023. | ||
